Table I.
Patient demographics, cancer characteristics, and cancer treatment in non-Hispanic white patients with melanoma by tumor thickness and stage from the California Cancer Registry (2004-2013)
| <1 mm not ulcerated |
<1 mm not ulcerated |
Stage IIA |
Stage IIB |
Stage III |
Stage IV |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 30,873 [71.6%]) |
(n = 1092 [2.5%]) |
(n = 3447 [8.0%]) |
(n = 2350 [5.5%]) |
(n = 3137 [7.3%]) |
(n = 2209 [5.1%]) |
||||||||
| Characteristic | n | % | n | % | n | % | n | % | n | % | n | % | P value |
| Sex | |||||||||||||
| Male | 17,964 | 58.2% | 698 | 63.9% | 2242 | 65.0% | 1593 | 67.8% | 2124 | 67.7% | 1575 | 713% | |
| Female | 12,909 | 41.8% | 394 | 36.1% | 1205 | 35.0% | 757 | 322% | 1013 | 323% | 634 | 28.7% | <.001 |
| Age at diagnosis, y | |||||||||||||
| <5 | 1970 | 6.4% | 48 | 4.4% | 133 | 3.9% | 59 | 25% | 224 | 7.1% | 78 | 35% | |
| 35–44 | 3023 | 9.8% | 76 | 7.0% | 175 | 5.1% | 103 | 4.4% | 291 | 93% | 116 | 53% | |
| 45–54 | 5710 | 185% | 154 | 14.1% | 459 | 133% | 248 | 10.6% | 581 | 185% | 317 | 14.4% | |
| 55 64 | 7033 | 22.8% | 233 | 213% | 647 | 18.8% | 444 | 18.9% | 719 | 22.9% | 540 | 24.4% | |
| 65–74 | 6288 | 20.4% | 226 | 20.7% | 712 | 20.7% | 503 | 21.4% | 579 | 185% | 498 | 225% | |
| >75+ | 6849 | 22.2% | 355 | 325% | 1321 | 383% | 993 | 423% | 743 | 23.7% | 660 | 29.9% | <.001 |
| SES | |||||||||||||
| Lowest SES | 1772 | 5.7% | 78 | 7.1% | 244 | 7.1% | 191 | 8.1% | 259 | 83% | 204 | 92% | |
| Lower-middle SES | 3439 | 11.1% | 163 | 14.9% | 490 | 142% | 345 | 14.7% | 447 | 142% | 341 | 15.4% | |
| Middle SES | 5341 | 173% | 192 | 17.6% | 666 | 193% | 446 | 19.0% | 633 | 202% | 447 | 202% | |
| Higher-middle SES | 7473 | 242% | 259 | 23.7% | 795 | 23.1% | 546 | 232% | 718 | 22.9% | 527 | 23.9% | |
| Highest SES | 10,874 | 352% | 326 | 29.9% | 1011 | 293% | 676 | 28.8% | 880 | 28.1% | 549 | 24.9% | |
| Missing | 1974 | 6.4% | 74 | 6.8% | 241 | 7.0% | 146 | 62% | 200 | 6.4% | 141 | 6.4% | <0.001 |
| Year of diagnosis | |||||||||||||
| 2004–2006 | 9683 | 31.4% | 332 | 30.4% | 1056 | 30.6% | 704 | 30.0% | 942 | 30.0% | 670 | 303% | |
| 2007–2009 | 10,791 | 35.0% | 334 | 30.6% | 1060 | 30.8% | 747 | 31.8% | 1002 | 31.9% | 728 | 33.0% | |
| 2010–2013 | 10,399 | 33.7% | 426 | 39.0% | 1331 | 38.6% | 899 | 383% | 1193 | 38.0% | 811 | 36.7% | <.001 |
| Histology | |||||||||||||
| Malignant | CO | 605% | 646 | 592% | 2052 | 595% | 1368 | 582% | 1871 | 59.6% | 1985 | 89.9% | |
| melanoma, NOS | |||||||||||||
| Nodular melanoma | 299 | 1.0% | 130 | 11.9% | 660 | 19.1% | 609 | 25.9% | 690 | 22.0% | 158 | 72% | |
| Lentigo maligna | 1800 | 5.8% | 37 | 3.4% | 66 | 1.9% | 30 | 13% | 20 | 0.6% | 2 | 0.1% | |
| melanoma | |||||||||||||
| Superficial spreading | 9977 | 323% | 275 | 252% | 629 | 182% | 313 | 133% | 497 | 15.8% | 57 | 2.6% | |
| melanoma | |||||||||||||
| Acral lentiginous | 120 | 0.4% | 4 | 0.4% | 40 | 12% | 30 | 13% | 59 | 1.9% | 7 | 03% | <.001 |
| melanoma | |||||||||||||
| Lymph node biopsy | |||||||||||||
| No | 26,494 | 853% | 725 | 66.4% | 1454 | 422% | 1096 | 46.6% | 1742 | 555% | 2021 | 915% | |
| Yes | 4332 | 14.0% | 364 | 333% | 1988 | 57.7% | 1252 | 533% | 1385 | 442% | 98 | 4.4% | |
| Unknown | 47 | 02% | 3 | 0.4% | 5 | 0.1% | 2 | 0.1% | 10 | 03% | 90 | 4.1% | <.0001 |
| Chemotherapy | |||||||||||||
| No | 30,738 | 99.6% | 1075 | 98.4% | 3415 | 99.1% | 2308 | 982% | 2824 | 90.0% | 1525 | 69.0% | |
| Yes | 72 | 02% | 14 | 13% | 28 | 0.8% | 36 | 15% | 275 | 83% | 647 | 293% | |
| Unknown | 63 | 02% | 3 | 03% | 4 | 0.1% | 6 | 03% | 38 | 12% | 37 | 1.7% | <.0001 |
| Immunotherapy | |||||||||||||
| No | 30,726 | 995% | 1060 | 97.1% | 3394 | 985% | 2262 | 962% | 2439 | 773% | 1972 | 893% | |
| Yes | 96 | 03% | 26 | 2.4% | 46 | 13% | 79 | 3.4% | 640 | 20.4% | 224 | 10.1% | |
| Unknown | 51 | 02% | 6 | 0.6% | 7 | 02% | 9 | 0.4% | 58 | 13% | 13 | 0.6% | <.0001 |
NOS. Not otherwise specified; SES, socioeconomic status.